MA54063A - Nouveau sel d'un inhibiteur de bcl-2, forme cristalline associée, son procédé de préparation et compositions pharmaceutiques le contenant - Google Patents
Nouveau sel d'un inhibiteur de bcl-2, forme cristalline associée, son procédé de préparation et compositions pharmaceutiques le contenantInfo
- Publication number
- MA54063A MA54063A MA054063A MA54063A MA54063A MA 54063 A MA54063 A MA 54063A MA 054063 A MA054063 A MA 054063A MA 54063 A MA54063 A MA 54063A MA 54063 A MA54063 A MA 54063A
- Authority
- MA
- Morocco
- Prior art keywords
- bcl
- inhibitor
- preparing
- pharmaceutical compositions
- crystalline form
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306430 | 2018-10-31 | ||
| PCT/EP2019/079621 WO2020089281A1 (fr) | 2018-10-31 | 2019-10-30 | Nouveau sel d'un inhibiteur de bcl-2, forme cristalline associée, son procédé de préparation et compositions pharmaceutiques le contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54063A true MA54063A (fr) | 2021-09-08 |
| MA54063B1 MA54063B1 (fr) | 2023-06-28 |
Family
ID=64270773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54063A MA54063B1 (fr) | 2018-10-31 | 2019-10-30 | Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenant |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20210355108A1 (fr) |
| EP (1) | EP3873894B1 (fr) |
| JP (2) | JP2022506137A (fr) |
| KR (1) | KR20210092750A (fr) |
| CN (1) | CN112969693A (fr) |
| AR (1) | AR116921A1 (fr) |
| AU (1) | AU2019370926B2 (fr) |
| BR (1) | BR112021007194A2 (fr) |
| CA (1) | CA3117559C (fr) |
| CL (1) | CL2021000947A1 (fr) |
| CO (1) | CO2021005077A2 (fr) |
| CR (1) | CR20210211A (fr) |
| CY (1) | CY1126057T1 (fr) |
| DK (1) | DK3873894T3 (fr) |
| DO (1) | DOP2021000074A (fr) |
| EA (1) | EA202191143A1 (fr) |
| ES (1) | ES2943511T3 (fr) |
| FI (1) | FI3873894T3 (fr) |
| GE (2) | GEP20237494B (fr) |
| HR (1) | HRP20230563T1 (fr) |
| HU (1) | HUE062000T2 (fr) |
| IL (1) | IL282565A (fr) |
| JO (1) | JOP20210072A1 (fr) |
| LT (1) | LT3873894T (fr) |
| MA (1) | MA54063B1 (fr) |
| MX (1) | MX2021004934A (fr) |
| MY (1) | MY202547A (fr) |
| NI (1) | NI202100025A (fr) |
| PE (1) | PE20211503A1 (fr) |
| PH (1) | PH12021550790A1 (fr) |
| PL (1) | PL3873894T3 (fr) |
| PT (1) | PT3873894T (fr) |
| RS (1) | RS64236B1 (fr) |
| SG (1) | SG11202103594XA (fr) |
| SI (1) | SI3873894T1 (fr) |
| TW (1) | TWI791916B (fr) |
| WO (1) | WO2020089281A1 (fr) |
| ZA (1) | ZA202102783B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3155067A1 (fr) | 2019-09-27 | 2021-04-01 | Shanghai Flyco Electrical Appliance Co., Ltd. | Rasoir electrique, appareil electromenager portatif, systeme de rasoir electrique et procede de commande |
| CA3190276A1 (fr) | 2020-07-31 | 2022-02-03 | Les Laboratoires Servier | Combinaison d'un inhibiteur de bcl-2 et d'un agent hypomethylant pour le traitement de cancers, utilisations et compositions pharmaceutiques associees |
| WO2022090443A1 (fr) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1 |
| EP4313964A1 (fr) | 2021-03-24 | 2024-02-07 | Les Laboratoires Servier | Nouveau procédé de synthèse de dérivés de 5-{5-chloro-2-[(3s)-3-[(morpholin-4-yl)méthyl]-3,4-dihydroisoquinoléine-2(1h )-carbonyl]phényl}-1,2-diméthyl-1h-pyrrole-3-acide carboxylique et son application pour la production de composés pharmaceutiques |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US7432398B2 (en) * | 2005-01-06 | 2008-10-07 | Cj Corporation | Inorganic acid salts of sibutramine |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| CN101962387B (zh) * | 2010-09-13 | 2013-01-30 | 成都雅途生物技术有限公司 | 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法 |
| CN103664753B (zh) * | 2012-09-04 | 2017-04-26 | 上海迪赛诺化学制药有限公司 | 制备阿扎那韦硫酸氢盐a型结晶的方法 |
| FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US10351559B2 (en) * | 2015-04-15 | 2019-07-16 | Beigene, Ltd. | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
-
2019
- 2019-10-30 CA CA3117559A patent/CA3117559C/fr active Active
- 2019-10-30 MY MYPI2021002028A patent/MY202547A/en unknown
- 2019-10-30 LT LTEPPCT/EP2019/079621T patent/LT3873894T/lt unknown
- 2019-10-30 BR BR112021007194-6A patent/BR112021007194A2/pt unknown
- 2019-10-30 FI FIEP19800947.4T patent/FI3873894T3/fi active
- 2019-10-30 CR CR20210211A patent/CR20210211A/es unknown
- 2019-10-30 GE GEAP201915620A patent/GEP20237494B/en unknown
- 2019-10-30 PT PT198009474T patent/PT3873894T/pt unknown
- 2019-10-30 EP EP19800947.4A patent/EP3873894B1/fr active Active
- 2019-10-30 PL PL19800947.4T patent/PL3873894T3/pl unknown
- 2019-10-30 PE PE2021000597A patent/PE20211503A1/es unknown
- 2019-10-30 GE GEAP202215620A patent/GEAP202215620A/en unknown
- 2019-10-30 MX MX2021004934A patent/MX2021004934A/es unknown
- 2019-10-30 DK DK19800947.4T patent/DK3873894T3/da active
- 2019-10-30 US US17/286,936 patent/US20210355108A1/en not_active Abandoned
- 2019-10-30 EA EA202191143A patent/EA202191143A1/ru unknown
- 2019-10-30 WO PCT/EP2019/079621 patent/WO2020089281A1/fr not_active Ceased
- 2019-10-30 AU AU2019370926A patent/AU2019370926B2/en active Active
- 2019-10-30 CN CN201980071289.7A patent/CN112969693A/zh active Pending
- 2019-10-30 MA MA54063A patent/MA54063B1/fr unknown
- 2019-10-30 TW TW108139360A patent/TWI791916B/zh not_active IP Right Cessation
- 2019-10-30 KR KR1020217015833A patent/KR20210092750A/ko not_active Withdrawn
- 2019-10-30 HU HUE19800947A patent/HUE062000T2/hu unknown
- 2019-10-30 SG SG11202103594XA patent/SG11202103594XA/en unknown
- 2019-10-30 AR ARP190103143A patent/AR116921A1/es not_active Application Discontinuation
- 2019-10-30 HR HRP20230563TT patent/HRP20230563T1/hr unknown
- 2019-10-30 ES ES19800947T patent/ES2943511T3/es active Active
- 2019-10-30 SI SI201930557T patent/SI3873894T1/sl unknown
- 2019-10-30 RS RS20230347A patent/RS64236B1/sr unknown
- 2019-10-30 JP JP2021523309A patent/JP2022506137A/ja active Pending
-
2021
- 2021-04-09 NI NI202100025A patent/NI202100025A/es unknown
- 2021-04-09 PH PH12021550790A patent/PH12021550790A1/en unknown
- 2021-04-12 JO JOP/2021/0072A patent/JOP20210072A1/ar unknown
- 2021-04-16 CL CL2021000947A patent/CL2021000947A1/es unknown
- 2021-04-21 DO DO2021000074A patent/DOP2021000074A/es unknown
- 2021-04-21 CO CONC2021/0005077A patent/CO2021005077A2/es unknown
- 2021-04-22 IL IL282565A patent/IL282565A/en unknown
- 2021-04-26 ZA ZA2021/02783A patent/ZA202102783B/en unknown
-
2023
- 2023-05-18 CY CY20231100236T patent/CY1126057T1/el unknown
-
2024
- 2024-08-27 US US18/816,347 patent/US20240417390A1/en active Pending
- 2024-11-26 JP JP2024205589A patent/JP2025028968A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007688B (en) | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods, and uses thereof | |
| EP3954693A4 (fr) | Forme cristalline d'un inhibiteur d'egfr et procédé de préparation associé | |
| EP3502103A4 (fr) | Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation | |
| PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| EP3815540A4 (fr) | Composition de poudre d'édulcorant et son procédé de préparation | |
| EP3412672A4 (fr) | Forme cristalline a d'un agoniste de tlr7, son procédé de préparation et son utilisation | |
| MY193177A (en) | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use therepf | |
| EP3705118A4 (fr) | Composition pour forme posologique solide orale présentant une désintégration améliorée et son procédé de préparation | |
| EP3470400A4 (fr) | Forme cristalline de l'ozanimod, forme cristalline de son hydrochloride et son procédé de préparation | |
| EP3502105A4 (fr) | Forme polymorphe d'un composé inhibiteur de kinase, composition pharmaceutique le contenant, son procédé de préparation et son utilisation | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| NZ735736A (en) | Acetate salt of buprenorphine and methods for preparing buprenorphine | |
| ZA202102783B (en) | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| EP3412674A4 (fr) | Sel de trifluoroacétate d'un agoniste de tlr7, sa forme cristalline b, ses procédés de préparation et ses utilisations | |
| EP3766884A4 (fr) | Forme cristalline et type de sel d'un composé triazolopyrimidine et procédé de préparation associé | |
| EP3825099A4 (fr) | Composition pour mise en forme tridimensionnelle et procédé de production d'article dentaire | |
| EP3722286A4 (fr) | Sel d'un dérivé de phénylpropionamide et son procédé de préparation | |
| EP3719020A4 (fr) | FORME CRISTALLINE D'UN INHIBITEUR DE ß-LACTAMASE ET SON PROCÉDÉ DE PRÉPARATION | |
| EP3725786A4 (fr) | Forme cristalline et forme de sel d'un inhibiteur de tgf-bri et procédé de préparation correspondant | |
| EP3521276A4 (fr) | Forme cristalline, forme de sel, et procédé de préparation d'inhibiteur de tyrosine kinase | |
| MA54379A (fr) | Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant | |
| WO2019240698A3 (fr) | Compositoins pharmaceutiques orales comprenant du posaconazole | |
| EP3929178A4 (fr) | Forme cristalline d'un hydrate d'hydrochlorure de valnemulin, son procédé de préparation et composition pharmaceutique contenant la forme cristalline | |
| EP3877379A4 (fr) | Forme cristalline de chlorhydrate de nilotinib, son procédé de préparation et composition pharmaceutique le contenant | |
| MA53088A (fr) | Dérivés d'amino-pyrimidonyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant |